Palisade Bio Enters Licensing Agreement with Giiant Pharma, Shares Jump 110%

 Palisade Bio (Nasdaq: PALI) has entered into a licensing agreement with Giiant Pharma, giving it the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform focused on therapies for the multi-billion dollar inflammatory bowel disease (IBD) market.

J.D. Finley, Chief Executive Officer of Palisade Bio, said, “We are incredibly pleased to enter into this licensing agreement with Giiant and transform our GI-focused development pipeline. With current IBD therapies achieving minimal rates of efficacy, there remains a strong need for orally administered, novel solutions that overcome the limitations of current biological medications.”

Highlights

The licensed technologies include Giiant’s precision delivery technology platform and multiple product candidates, including the lead asset in development, GT-2108, an orally administered, gut-restricted, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by moderate-to-severe ulcerative colitis.

Under the terms of the license, Palisade obtained the rights to develop, manufacture, and commercialize all compounds from Giiant, existing now and in the future, and any product containing or delivering any licensed compound, in any formulation or dosage for all human and non-human therapeutic uses for any and all indications worldwide.

Palisade stated that the transaction underscores its commitment to improving gastrointestinal health and represents an exciting acceleration in its focus to advance innovative therapeutics for the treatment of IBD.

About Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology with human disease to advance novel therapeutics that target and improve the integrity of the intestinal barrier.

About Giiant Pharma

Giiant Pharma (www.giiant.com), a preclinical-stage biotech company, designs gut-restricted small molecules, drug therapeutics with various biological targets in gastroenterology owing to its proprietary Precision Delivery technology platform. Its first lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrug, with vastly improved drug tolerability and enhanced therapeutic effect.

Share This Article

 

About the Author

Palisade Bio Enters Licensing Agreement with Giiant Pharma, Shares Jump 110%

Editor Prism MarketView